A new national guideline provides evidence-based recommendations for diagnosing, treating, and preventing pediatric ...

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five and poses a persistent threat to child health worldwide.

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five and poses a persistent ...

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...

In China, RSV accounted for an estimated 3.5 million ALRTI cases and up to 950,000 hospitalizations in 2019—nearly one-quarter of the global burden.

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that ...

Follow the latest RSV cases news stories and headlines. Get breaking news alerts when you download the ABC News App and subscribe to RSV cases notifications.

WHO Director-General Tedros Adhanom Ghebreyesus said it was a “moral imperative” to determine how COVID began, noting that ...

MPV tends to hit hardest in young children, older adults and people with weakened immune systems. A virologist explains.

Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.